

MnVFC Announcement

Date: November 20, 2023
To: MnVFC Providers
From: MnVFC Program
Re: **Nirsevimab Orders and RSV Product Errors**

Please route to:

- Clinical supervisor
- Medical director
- Clinic manager
- Clinic staff
- Pharmacy
- Vaccine staff

Nirsevimab (Beyfortus) orders

A new Nirsevimab (Beyfortus) special ordering event will open on Wednesday, Nov. 22 through Thursday, Nov. 30. **The requests submitted for this ordering event should reflect the number of doses that sites will need for the remainder of the 2023-2024 season.** You can access this event in MIIC's vaccine management section by clicking "request special event vaccine" and selecting the "2023-2024 Nirsevimab Orders" event from the dropdown menu. We will fill orders on a rolling basis as CDC makes the product available to us to ensure equitable distribution across the state. We expect all doses available to us for the season to be distributed by the end of the calendar year unless more doses are released by the manufacturer.

As a reminder, borrowing between VFC and private stock is allowed this season. However, if you are accepting VFC vaccine you must provide access to Nirsevimab to VFC-eligible children. It is not acceptable to use VFC stock only on privately insured children. Please note, you may need to replace stock next season that is borrowed this season. It is imperative that you maintain good documentation on your borrowing report if you choose to do this.

IMPORTANT! Reports of adult RSV vaccine products improperly given to infants

Do not inadvertently give RSV vaccines (Abrysvo or Arexvy) to infants. CDC has received several reports of this happening when the infant should have received the RSV monoclonal antibody (nirsevimab). Vaccine providers who carry both nirsevimab (for use in infants and young children) and RSV vaccines (for use in older adults and pregnant people) should be especially diligent in following vaccine administration safety procedures to prevent errors.

To minimize risk of errors, store RSV vaccine and monoclonal antibodies in their original packaging on different shelves and clearly label them. Also ensure the seven rights of vaccine administration have been performed:

- Right patient
- Right time
- Right vaccine and diluent
- Right dosage
- Right route, needle length, and technique
- Right site
- Right documentation

In the event RSV vaccine (Abrysvo or Arexvy) was administered to an infant:

- Inform the provider and the parent/guardian of the error.
- Email CDC nipinfo@cdc.gov (and "Cc" MDH health.vaccineSME@state.mn.us) for guidance on next steps.
- Promptly report the error to the [Vaccine Adverse Event Reporting System \(VAERS\)](https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html) (www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html).